These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 18931138)

  • 1. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.
    Morello J; Rodríguez-Novoa S; Jiménez-Nácher I; Soriano V
    J Antimicrob Chemother; 2008 Dec; 62(6):1174-80. PubMed ID: 18931138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.
    Morello J; Rodríguez-Nóvoa S; Cantillano AL; González-Pardo G; Jiménez I; Soriano V
    Ther Drug Monit; 2007 Dec; 29(6):802-6. PubMed ID: 18043479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.
    Chan AH; Partovi N; Ensom MH
    Ann Pharmacother; 2009 Dec; 43(12):2044-63. PubMed ID: 19920162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evidence-based therapeutic drug monitoring for ribavirine].
    Solas C; Paré M; Quaranta S; Stanke-Labesque F;
    Therapie; 2011; 66(3):221-30. PubMed ID: 21819806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribavirin in chronic hepatitis C: past and future.
    Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
    Tran HA; Malcolm Reeves GE; Gibson R; Attia JR
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1163-8. PubMed ID: 19682190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
    Tanioka D; Iwasaki Y; Araki Y; Osawa T; Ikeda H; Ando M; Kobashi H; Sakaguchi K; Shiratori Y; Yamamoto K
    Liver Int; 2009 May; 29(5):721-9. PubMed ID: 19141025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients.
    D'Avolio A; Ibañez A; Sciandra M; Siccardi M; de Requena DG; Bonora S; Di Perri G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 835(1-2):127-30. PubMed ID: 16569520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver function under interferon/ribavirin therapy of chronic hepatitis C.
    Stintzing S; Schmitt C; Ocker M; Ganslmayer M; Zopf S; Gahr S; Hahn EG; Herold C
    Hepatogastroenterology; 2009; 56(90):462-5. PubMed ID: 19579621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?
    Aghemo A; Rumi MG; Prati GM; Colombo M
    Hepatology; 2009 Feb; 49(2):702-3; author reply 703-4. PubMed ID: 19177585
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of pre-analytical conditions on plasma ribavirin concentrations.
    Gandia P; Trancart S; Nicot F; Barange K; Alric L; Izopet J; Séraissol P; Lavit M; Houin G
    Arzneimittelforschung; 2010; 60(10):636-9. PubMed ID: 21125815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.
    Dev A; Patel K; Muir A; McHutchison JG
    Am J Gastroenterol; 2003 Nov; 98(11):2344-7. PubMed ID: 14638332
    [No Abstract]   [Full Text] [Related]  

  • 14. [Not Available].
    Solas C; Paré M; Quaranta S; Stanke-Labesque F;
    Therapie; 2011; 66(3):221-30. PubMed ID: 27393202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon alpha. Effect, indications, therapy monitoring and side-effects].
    Kraus MR; Wilms K
    Internist (Berl); 2000 Dec; 41(12):1399-404. PubMed ID: 11189075
    [No Abstract]   [Full Text] [Related]  

  • 16. Measuring Plasma Concentrations of Ribavirin: First Report From a Quality Control Program.
    Smolders EJ; Kan R; de Kanter CT; van Luin M; Aarnoutse RE; Touw DJ; Burger DM
    Ther Drug Monit; 2016 Oct; 38(5):646-7. PubMed ID: 27355493
    [No Abstract]   [Full Text] [Related]  

  • 17. Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?
    D'Avolio A; Cusato J; Calcagno A; Di Perri G
    J Hepatol; 2013 Sep; 59(3):633-4. PubMed ID: 23707369
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to: "estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?".
    Rau M; Geier A
    J Hepatol; 2013 Sep; 59(3):634-5. PubMed ID: 23707364
    [No Abstract]   [Full Text] [Related]  

  • 19. Ribavirin: is there a risk to hospital personnel? Infectious Diseases and Immunization Committee, Canadian Paediatric Society.
    CMAJ; 1991 Feb; 144(3):285-6. PubMed ID: 1989706
    [No Abstract]   [Full Text] [Related]  

  • 20. Ribavirin therapy in chronic delta hepatitis.
    Buti M; Esteban R; Jardi R; Rodriguez F; Guardia J
    J Hepatol; 1993 Sep; 19(2):318. PubMed ID: 8301069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.